Benjamin Click, MD, staff gastroenterologist, the Cleveland Clinic, discusses the process to select the right biologic for a patient with inflammatory bowel disease (IBD).
Transcript
I think we'd be remiss not to acknowledge the third party in the room when a physician and a patient are interacting and making treatment decisions, and that's the payer in the mix. Unfortunately, a lot of our decisions in medicine do have some payer implications in what a person's insurance will or won't cover. And so that's certainly a consideration when we talk about patients, so there is access impact with regards to what the payer will cover.
From an individual patient decision-making process, there are a lot of considerations that go into how we choose which biologic medication to use. So first is the efficacy. What do we think this particular biologic will do to the disease process itself? Then we talk about risks. What are the risks with each biologic medication? And there's several different classes. We talk about risk of infections, risk of malignancy, risk of potential rejection of the medication by the body over time. And…we talk about the dosing strategy of each medication because they all do differ in some way, shape, or form.
And so generally, when I'm talking to a patient, we talk about their individual disease state. We also talk about what do I think will happen with their disease if left under or untreated over time, and how do we kind of find the common avenue with regards to all those different factors and choosing a biologic medication, and of course, recognizing that we also have to consider which will be covered from an insurance standpoint.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.